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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
Primary objective
To assess the effectiveness of psychosocial interventions at reducing the substance misuse (alcohol and/or illicit drugs excluding tobacco)
of parents with children of dependent age (from birth to 21years). Intervention impact will be examined separately for different
substances.
Secondary objectives
To examine whether interventions can increase drug and/or alcohol treatment engagement, retention and completion; affect the welfare
of the child; whether intervention effects differ by intervention type and duration or according to who receives them.
B A C K G R O U N D
Description of the condition
Substance misuse, defined as dependence upon, or regular ex-
cessive consumption, of psychoactive substances leading to phys-
ical, mental or social problems (NICE 2016), is a major pub-
lic health concern worldwide (Degenhardt 2013; World Health
Organization 2011). Whilst there is significant variation in con-
sumption levels globally, alcohol and drug use has been rising over
recent decades in many low-income countries, with high-income
countries currently experiencing the greatest burden (Degenhardt
2013; World Health Organization 2009). As well as contributing
tomore than 60 diseases, many fatalities are attributable to alcohol
misuse (Health and Social Care Information Centre 2013). In-
deed, alcohol misuse represents the fifth leading cause of morbid-
ity and premature death worldwide (Lim 2012), with 3.8% of all
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deaths being attributed to it (Rëhm 2009), and a further 0.4% of
deaths being attributed to illicit drug misuse (Degenhardt 2012).
Moreover, 4.6% of the global disability-adjusted life-years are at-
tributable to alcohol misuse (Rëhm 2009), and 0.8% to illicit drug
misuse (Degenhardt 2013). As well as causing a significant risk
to individuals, substance misuse is harmful to others, with alco-
hol being the most harmful substance (Nutt 2010). Indeed, there
are numerous social risks associated with alcohol and drug mis-
use including family disruption and deprivation (Holland 2014),
violent and anti-social behaviour (Hughes 2008), interpersonal
violence (Anderson 2009), and child abuse and neglect (Taplin
2015). Substance misuse may lead to dependence and associated
consequences for health, social stigma (Earnshaw 2013), and so-
cial exclusion (Anderson 2009).
Research estimates that between 5% and 30% of children in Eu-
ropean countries live with at least one parent who misuses sub-
stances (EMCDDA 2010). In the UK 30% of children under the
age of 16 years (3.3 to 3.5 million) live with at least one parent
who misuses alcohol, and 8% with a parent who misuses illicit
drugs (980,000) (Manning 2009). Almost 12% of children in the
USA (SAMHSA 2009), and 13% of children in Australia (Dawe
2007), live with at least one substance misusing parent. Many of
these children are infants. In the UK it is estimated that 124,500
babies under the age of one year live with at least one parent who
misuses alcohol, and 70,500 live with a parent who misuses illicit
drugs. In total, over 14% of UK infants are exposed to parental
problem-drinking or illicit drug use (Manning 2011).
In addition to well documented harms of substance misuse to the
individual user, parental substance misuse has been found to be
associated with adverse childhood experiences and poor outcomes
for children. Research has shown that children of parents whomis-
use substances are more likely to sustain an unintentional injury
(Barczyk 2013), as well as injuries of greater severity than chil-
dren whose parents do not misuse substances (Damashek 2009).
Children whose mothers’ medical records showed a history of
alcohol misuse have a significantly higher chance of long bone
fracture (Baker 2015) - as well as medicinal poisoning (Tyrrell
2012) - than those children whose mothers do not have a record
of alcohol misuse. Parental substance misuse has an impact upon
child mental health (Kelley 2010; Jääskeläinen 2016), with both
mothers’ and fathers’ substance misuse being significantly associ-
ated with childhood externalising disorders such as conduct dis-
order, oppositional defiant disorder (Kendler 2013; Torvik 2011),
and internalising disorders such as depression and anxiety dis-
order (Ohannessian 2012). Children whose parents misuse sub-
stances are significantly more likely to engage with early onset sub-
stance use (Malone 2002; Malone 2010), harmful substance mis-
use (Jääskeläinen 2016), and street-involvement (defined as home-
lessness or those young people who experience physical, psycho-
logical or social risks of street-culture) (Baker 2014), than children
whose parents do not misuse substances. Furthermore, parental
substance misuse is significantly associated with the development
of mental disorders and substance use disorders when children en-
ter adulthood (Donaldson 2016; Yoon 2013).
Due to the potentially negative impact on the child, parental sub-
stance misuse is often identified as a risk factor in child welfare
and child protection assessments. In the UK, 18% of all child-in-
need assessments identify parental drug misuse and 19% identify
parental alcohol misuse (Department for Education 2016), fur-
thermore, 52% of child protection cases have parental substance
misuse identified as a risk factor (Forrester 2000). In the USA
parental substance misuse has been associated with up to two-
thirds of all childmaltreatment cases (Traube 2012). Furthermore,
a study conducted in Finland found that children whose mothers
misused both alcohol and drugs were nine times more likely to
be placed in care than children of parents who did not misuse
substances (Raitasalo 2015). There have been a number of trials
of interventions relating to substance-using parents that sought to
address this risk factor by reducing the need for protective services,
and to promote family reunification. However, at present, there is
no agreed way to intervene. As such, there is a need to review the
literature systematically, in order to identify effective psychological
and social interventions to reduce parental substance misuse.
Description of the intervention
Interventions that address psychosocial substance misuse are non-
pharmacological therapeutic interventions delivered to individuals
or groups, which seek to tackle the psychological, social, personal
and relational problems associated with substance misuse. There
are many different psychosocial interventions, with approaches
and techniques that vary according to their theoretical underpin-
nings.Wewill include a range of psychosocial interventions within
this review. These include, but are not limited to: motivational
interviewing; cognitive behavioural therapy; psychodynamic ther-
apy; casemanagement; residential rehabilitation; parent skill train-
ing, couples therapy, and family therapy. This broad range of psy-
chosocial interventions maybe delivered to an individual, family
or delivered at a social level.
Motivational interviewing
Motivational interviewing is a person-centred, directive approach,
which seeks to resolve the conflict inherent in behaviour change
(Miller 1991). Unlike cognitive behavioural interventions, moti-
vation to change is not assumed. Rather ambivalence to change
is typical; motivation is viewed as malleable and formed within
the context of the therapist-client relationship. The therapist em-
ploys specific strategies to developmotivation, seeking to mobilise
the client’s inner resources and intrinsic motivation and, in doing
so, to enable the client to initiate and achieve behaviour change.
Motivational interviewing was first developed for use with alcohol
before being extended to drug treatment services (Miller 1983;
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Miller 2003). A recent systematic review and meta-analysis of mo-
tivational interviewing delivered as alongside or within medical
care found the approach to have a statistically significant effect
of modest size. This review found the approach was particularly
promising for a range of behaviours including alcohol and tobacco
use (Lundahl 2013).
Cognitive behavioural therapy
Cognitive behavioural therapy believes that an individual’s
thoughts, emotions and behaviour are connected (Meichenbaum
1977). Within the context of substance misuse, individuals are
perceived to hold dysfunctional beliefs about themselves and the
world around them (Marlatt 1985), and to exhibit behaviours
based upon a range of automatic and nonautomatic responses to
urges (Tiffany 1990). Through the development of self-awareness,
performing experiments, and development of coping strategies
and skills, individuals can alter their thoughts and feelings and
change their behaviour (Beck 1993).
Psychodynamic therapy
Psychodynamic therapy exists on a supportive-interpretive con-
tinuum, the essence of which is the exploration of the parts of
the self that are not known and are therefore unconscious. The
therapeutic approach involves a focus on the patient’s emotion,
active exploration of avoidance, identification of recurring themes,
discussion of past events, interpersonal relationships - including
that with the therapist - and exploration of the patient’s fears and
desires (Shedler 2010).
Case management
Case management is the organisation and co-ordination of inten-
sive treatment programmes within the community. This outpa-
tient approach emerged as an alternative to hospital and residential
units for the treatment of disorders including substance misuse
and mental health disorders (McLellan 1999).
Residential rehabilitation
Residential rehabilitation is an inpatient treatment programme
typically consisting of an intensive programme of individual and
group psychosocial interventions. There are a wide range of resi-
dential rehabilitation models including those based upon the 12-
step programme (Alcoholics Anonymous 2002) and therapeutic
community model (De Leon 2000). The treatment goal of resi-
dential rehabilitation units is predominately abstinence.
Parent skill training
The introduction of parent skill training in the late 1960s marked
a move towards parents, as well as professionals, being viewed as
having the potential to address children’s problematic behaviours
(Kaminski 2008). Alongside the appreciation that parents could
contribute to children’s desirable behaviours, there was an increas-
ing appreciation of the potential for parents to contribute to the
formation of undesirable behaviours (Bandura 1969). While, Ini-
tially, parenting programmes focussed on teaching parents skills to
manage and address children’s behaviour, they have proliferated to
include programmes designed to address poor parenting practices
(Barth 2005).
Couples therapy
Couple therapy for drug and alcohol problems involves both the
user and his/her partner attending therapy. The approach is in-
formedby research that showed ahigh prevalence of discordwithin
relationships where substance misuse is present (O’Farrell 1993),
in which a direct relationship exists between substance problems
and relationship difficulties (Raistrick 2006). The approach as-
sumes that resolving issues within a relationship, and promoting
relational support, will facilitate a positive change in substance
misuse (Klostermann 2011).
Family therapy
Family therapy is an approach that seeks to address problems
within the system of relationships, rather than treating individu-
als outside their central context. There are many forms of family
therapy, including multidimensional and systemic therapy. In a
similar way to couples therapy, the approach seeks to mobilise the
strengths and support within relationships, and seeks to address
issues systemically (Stratton 2011).
How the intervention might work
Individual level interventions, whilst they may vary in their theo-
retical stance and the determinants upon which they focus, share
the assumption that change must be located within the individual.
Motivational interviewing highlights the spirit of the approach as
being the effective therapeuticmechanism. This spirit is concerned
with a partnership between the therapist and patient, wherein
the patient’s autonomy is respected within strengths-based model
for promoting change (Miller 2013). Cognitive behavioural ap-
proaches assume that substance-abuse relapses can be prevented by
addressing skill deficits and enabling people to cope with high-risk
situations (Monti 1989). Family-level interventions, which may
include couples and families, assume these contexts to be a poten-
tial source of both stress and support, and therefore tend to seek
to affect relational and system change (Stratton 2011). Environ-
mental and ecological interventions delivered on a social level, for
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example housing and employment training, assume that change
must occur within the wider social context of the individual and
his/her ecological system (Slesnick 2013).
There is evidence that the longer an individual is retained in treat-
ment, the better the outcome will be (Simpson 2008). As such,
many interventions focus upon engaging and supporting retention
of the individual in a treatment programme, rather than focusing
upon the characteristics of the therapy itself. Interventions such
as case management (Dobkin 2002), and those that utilise peer
mentors (Pallaveshi 2014), focus upon providing support to deal
with life stresses and promote treatment engagement and reten-
tion. The therapeutic effect of shared experience and understand-
ing is emphasised within peer mentoring (Gates 2007).
Interventions designed for substance misusing parents are likely
to operate within a context of, or with the specific aim of, child
welfare. Given the well documented association between individ-
ual and family risk from parental substance use, an intervention
that reduces parental substance misuse is likely to benefit both
the parent and the child (Kaner 2016). The reverse hypothesis is
also evident within intervention logic models. Systemic therapy,
that is, those based upon attachment theory, and parenting skills
training may seek to enhance effective and acceptable parenting,
believing that improvement in parental understanding and abil-
ities is likely to bring about changes in substance use, and that
through this parents become aware of the incompatibility that ex-
ists between their substance use and positive parenting practices
(Catalano 1999).
Why it is important to do this review
There are a number of other Cochrane Reviews published or
planned that aim to investigate interventions for pregnant women
who use alcohol (Lui 2008), or illicit drugs (Terplan 2015), and
lactating women who drink alcohol (Cassidy Giglia 2012), as well
as for children of problem drinkers (McLaughlin 2014). However,
there are no Cochrane Reviews that have evaluated the effective-
ness of interventions for parental substance misuse after the birth
of a child. Moreover, there are no reviews that have investigated
interventions for substance misusing fathers. Pregnancy and the
postpartum period are periods in women’s lives that are often con-
sidered to be times of leverage and opportunity for change (Davies
2013; Daley 1998; McBride 2003). As such, the interventions of-
fered and their effects are likely to differ from thse during estab-
lished parenthood.
Given the significant evidence that substance misuse is harmful
to the individual, and that parental substance misuse is associ-
ated with a variety of problems for children, intervening with this
population is both a public health and safeguarding priority. De-
spite this, themajority of parents who use substances are untreated
(Forrester 2006). By reviewing the evidence of the effectiveness of
psychosocial interventions, this review will inform commissioners’
decisions about the type of interventions to invest in, and will also
inform practitioners working with substance misusing parents and
their children.
O B J E C T I V E S
Primary objective
To assess the effectiveness of psychosocial interventions at reduc-
ing the substance misuse (alcohol and/or illicit drugs excluding
tobacco) of parents with children of dependent age (from birth
to 21years). Intervention impact will be examined separately for
different substances.
Secondary objectives
To examine whether interventions can increase drug and/or alco-
hol treatment engagement, retention and completion; affect the
welfare of the child; whether intervention effects differ by inter-
vention type and duration or according to who receives them.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials (RCTs) includ-
ing individually and cluster-randomised designs, factorial design,
stepped wedge, and trials which have a quasi-experimental design.
Studies will only be included if they have a minimum follow-
up period of six months from the start of the intervention. This
will enable identification of both shorter-term (6-11 month) and
longer-term impacts (12 month and over).
Types of participants
Participants will be parents who misuse substances; this will in-
clude mothers and fathers of children (sons and daughters) under
the age of 21 years, regardless of custodial or residency status of
the children. Same sex parents and foster parents will be included.
Substance misuse includes themisuse of alcohol or illicit drugs (in-
cluding cannabis and prescription drugs which are used other than
in accordance with medical or legal guidance), or both. Studies
that consider interventions delivered to populations that include
both parents and non-parents will be excluded. Studies of parental
interventions where the child is the only misuser of substances will
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be excluded. Studies will be included if the parent has been iden-
tified as a substance misuser by a reliable, valid, formal assessment
(validated screening tool, assessment by a health or child welfare
practitioner) or diagnostic tool (DSM III, DSM IIIR, DSM IV,
ICD8, ICD 9, ICD 10), or both. The administration of agonist
or detoxifying prescriptions will be considered as a proxy mea-
sure of substance misuse in participants and therefore trials that
include people taking them will be eligible for inclusion. Studies
of primary prevention interventions, where adult participants are
not identified as substance misusers will be excluded. Intervention
studies for pregnant substance users only, where the intervention
phase is restricted to the prenatal period, will be excluded.
Types of interventions
Complex psychosocial interventions that target substance misuse
in parents directly or indirectly will be included in this review.
No limit will be placed upon duration, frequency or intensity of
intervention. Multiple-focused interventions will be included if
the impact of the intervention upon parental substance misuse
is assessed. Studies of pharmacological interventions only will be
excluded. Where a study combines a pharmacological component
with psychosocial interventions, this will be included providing
the comparison group meets the inclusion criteria.
Interventions may be delivered to an individual parent (directly
or via digital technologies), couples or the wider family unit. Ap-
proaches which seek to engage with individual parents may in-
clude, but are not limited to: motivational interview, cognitive
behavioural therapy, psychodynamic therapy, parental skill train-
ing, case management, and residential rehabilitation. Interven-
tions aimed at couples may include couples marital and relational
therapy, where one or both parents misuse substances. Family-
level interventions may include: home visits, supported housing,
family therapy and residential rehabilitation (parent and child fa-
cilities). Social level interventions may include support housing
interventions or those which aim to promote employment.
The intervention may be delivered by a variety of professionals as
well as non-professionals. Professional groups may include social
workers, drug and alcohol treatment specialists, nurses, psychia-
trists, psychotherapists and nurses. Non-professionals may include
peer interventionists, advocates, mentors and parents with previ-
ous personal experience of substance misuse or the child welfare
system, or both. Interventions may be delivered with an individ-
ual, couples or in a group context, including a family.
Control or comparison groups will include: no intervention, wait-
ing list/delayed treatment control arms, attention control, alter-
native active intervention, and treatment as usual.
Types of outcome measures
Primary outcomes
Parental substance misuse
The primary outcome is a reduction in the frequency of parental
substance misuse. Parental substance misuse will be considered to
have reduced if there is a reduction in the number of episodes of
heavy drinking (defined as five units or more at a time) or in the
frequency of illicit drug use from baseline to the follow-up assess-
ment (minimum period of six months). This may be reported in
a number of ways: percentage of days of use during follow-up pe-
riod; percentage of days of abstinence during follow-up period; or
percentage of days of use/abstinence by specified substance during
follow-up period. These measures will be converted to number of
days of heavy episodic drinking/illicit drug use in the past 30 days
to enable comparison between them.
Secondary outcomes
The secondary outcomes of interest concern are change in relation
to parental substance misuse and child welfare from baseline to
the follow-up assessment.
Parental substance misuse
• Amount of use measured as levels of use per using occasion
• Sustained abstinence during assessment period (measured as
the number of participants with continuous abstinence during
the treatment)
• Dependence/disorder symptomology measured by a
reliable, valid, formal assessment tool (such as the addiction
severity index) or diagnostic tool (DSM III, DSM IIIR, DSM
IV, ICD8, ICD 9, ICD 10), or both
• Number of participants engaged in structured treatment
(defined as attending at least one session of structured treatment)
• Retention in treatment measured as number of participants
completing the treatment
Child welfare outcomes:
• Child substance misuse (delayed onset, reduction in levels
of use)
• Change in legal status (measured as a reduction in the
number of children taken into care, reduction in the time for
which children are in care, increased rates of family reunification
following temporary care orders)
• Reduction in recorded child welfare incidents (including
incidents of maltreatment, abuse or neglect)
Search methods for identification of studies
We aim to identify all relevant RCTs regardless of language or pub-
lication status (published, unpublished, in press, or in progress).
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Electronic searches
The following databases will be searched from their inception:
• the Cochrane Drugs and Alcohol Group Specialised
Register via the Cochrane Register of Studies (CRS-Web);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library;
• MEDLINE (Ovid) (1966 onwards);
• Embase (Ovid) (from 1974 onwards);
• PsycINFO (Ovid) (1806 onwards);
• CINAHL - Cumulative Index to Nursing & Allied Health
Lierature (1982 onwards);
• Applied Social Science (ASSIA) (1987 onwards);
• Sociological Abstracts (1963 onwards);
• Social Science Citation Index (SSCI) (1956 onwards);
• Scopus (1960 onwards).
The subject strategies for databases will be modelled on the search
strategy designed for MEDLINE in Appendix 1. Where appro-
priate, these will be combined with subject strategy adaptations of
the highly sensitive search strategy designed by Cochrane for iden-
tifying randomized controlled trials and controlled clinical trials
(as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Lefebvre 2011).
We will search the following trials registries:
• The World Health Organization International Clinical
Trials Registry Platform (www.who.int/trialsearch);
• ClinicalTrials.gov (www.clinicaltrials.gov);
• TRoPHI - The Trials Register of Promoting Health
Interventions (eppi.ioe.ac.uk/webdatabases/Search.aspx).
Searching other resources
Wewill handsearch the reference lists of relevant studies to identify
further relevant studies, as well as contacting authors who publish
in the field to identify ongoing trials and unpublished work. In
addition, we will search the reference lists of relevant Cochrane
Reviews.
Data collection and analysis
Selection of studies
We will import all references obtained from databases and other
resources into Endnote and remove duplicates. The use of a refer-
ence management software will promote consistency of reference
screening. Two researchers will independently screen all titles and
abstracts using the specified inclusion and exclusion criteria, re-
trieve full-text papers for potentially eligible studies and will eval-
uate these. They will resolve any discrepancies at each stage by
discussion, or by consulting a third researcher, if consensus can
not be reached. We will not apply any language restrictions. We
will translate articles written in languages other than English that
we consider to be potentially relevant from inspection of the title
and abstract.
Data extraction and management
Two researchers will independently extract the data from the in-
cluded studies using a standard data extraction form. Two review-
ers will pilot the data extraction form to ensure it effectively cap-
tures the data relevant to this review. Wewill resolve disagreements
by discussion and by consulting a third researcher if consensus
cannot be reached. We will extract the following data.
• Author details, title, unique identifier and date
• Eligibility verification and reason for exclusion
• Key features of the study: aim, design, setting
• Participant details: inclusion/exclusion criteria, baseline
characteristics, number entering trial, number randomized to
intervention groups
• Intervention and comparator details: duration, frequency,
intensity, professional delivering intervention, intervention type,
theoretical underpinning
• Outcome measures: pre and post intervention, units of
measurement
• Duration of follow-up(s) and attrition
• Measures for primary and secondary outcomes of interest at
each time point
• Method of analysis
Where multiple papers are included that relate to one trial, we will
identify an index paper and we will extract data from the index
and linked papers on one data extraction form.
Assessment of risk of bias in included studies
Two researchers will independently assess each study for risk of
bias. Disagreements will be resolved by discussion and where nec-
essary a third researcher will independently assess the study to en-
able agreement to be reached. The ’Risk of bias’ assessment for
RCTs used in this review will be conducted using the criteria rec-
ommended in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). This two-part, domain-based tool
addresses seven domains: random sequence generation and allo-
cation concealment (selection bias); blinding of participants and
providers (performance bias); blinding of outcome assessor (de-
tection bias); incomplete outcome data (attrition bias); selective
outcome reporting (reporting bias); and other sources of bias. The
first part of the tool involves describing what was reported to have
happened in the study. The second part of the tool involves as-
signing a judgement relating to the risk of bias for that entry, in
terms of low, high or unclear risk. To make these judgments we
will use the criteria indicated by the Cochrane Handbook for Sys-
tematic Reviews of Interventions adapted to the addiction field (see
Appendix 2 for details).
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Wewill address the domains of sequence generation and allocation
concealment (avoidance of selection bias) in the tool by a single
entry for each study.Wewill consider blinding of participants, per-
sonnel and outcome assessor (avoidance of performance bias and
detection bias) separately for objective outcomes (e.g. dropout, use
of substance of abuse measured by urine analysis, subjects engaged
and/or retained in further treatments, number of child welfare in-
cident reports, legal and care status of the child) and subjective
outcomes (e.g. participant self-reported use of substance). We will
consider incomplete outcome data (avoidance of attrition bias) for
all outcomes except for dropout from the treatment, which is very
often the primary outcome measure in trials on addiction. We will
use ’Risk of bias’ assessments to carry out sensitivity analyses (see
Sensitivity analysis).
Measures of treatment effect
We will analyse dichotomous outcome data by calculating the risk
ratio (RR) for each trial with the uncertainty in each result being
expressed with a 95% confidence interval (CI). We will analyse
continuous outcome by calculating mean differences (MDs), if
all studies use the same measurement scale. We will use standard-
ised mean differences (SMD) if studies use different measurement
scales to measure the same outcome, each with 95% confidence
intervals.
Unit of analysis issues
In studies that compare more than one intervention arm to a con-
trol arm, we will combine the relevant intervention groups into
a single group and we will compare it with the control to avoid
double counting of participants in the control groups. When tri-
als use a factorial design, we will combine sample size, mean and
standard deviation from separate intervention arms in accordance
with Cochrane recommendations (Higgins 2011). Cluster ran-
domized trials will be considered for this review, as randomisation
may occur by recruitment setting. We anticipate that the investi-
gators will have controlled for the susceptibility of cluster designs
to unit-of-analysis error and artificially small P values (Higgins
2011). Where this is not the case, we will contact authors and re-
quest participant data to enable the calculation of the intracluster
correlation coefficient (ICC).
Dealing with missing data
Wewill contact authors to try to obtain missing data.Where this is
impossible, we will attempt to estimate missing outcome measures
using other outcome measures provided; for example, estimating
quantity of alcohol consumed using data about frequency and
intensity of consumption. Wewill use data from intention-to-treat
analyses in preference to completer-only data, and we will contact
authors if insufficient data are provided, to enable intention-to-
treat analysis.Wewill extract post-intervention outcomes reported
asmean and standard deviations for synthesis, butwewill usemean
change scores if post intervention outcome data are not available.
If a study fulfils the inclusion criteria, but does not provide useful
data on outcomes to be extracted or included in themeta-analyses,
we will report this in the characteristic of included studies table
and in the main text.
Assessment of heterogeneity
It is anticipated that studies included in this review will be hetero-
geneous with regard to participants, interventions, substance use
targeted and outcomes analyzed. We will assess the magnitude of
heterogeneity using the I2 statistic, and the statistical significance
of the heterogeneity using P values derived fromChi2 tests (Deeks
2001). We will consider a P value less than 0.05 to be significant,
and I2 values higher than 50% to be indicative of substantial het-
erogeneity, although we will interpret the percentage within the
context of the size and direction of effects (Higgins 2011; Ryan
2014). We will conduct subgroup analysis to investigate hetero-
geneous results, should the data be available.
Assessment of reporting biases
We will investigate publication bias using funnel plots, plotting
the study effect size against the sample size (if a minimum number
of 10 studies are included in a meta-analysis). If asymmetry is
apparent, we will consider and discuss possible reasons for it.
Data synthesis
If studies are sufficiently homogeneous to enable meta-analysis,
we will pool the data for each outcome using a random-effects
model because a certain degree of heterogeneity is expected. We
will perform separate meta-analyses for the following types of sub-
stance use/misuse: opioids, cocaine, alcohol, cannabis, and poly-
substance. The meta-analysis will be performed using Review
Manager 5 (ReviewManager 2014). The method of meta-analysis
used will depend upon the available outcome data (dichotomous,
ordinal, continuous) as discussed in Chapter 9 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We are anticipating heterogeneity between studies. The magni-
tude of this may prohibit meta-analysis. If this is the case, we will
conduct a narrative synthesis, using appropriate headings to illu-
minate the findings of the included studies. These headings may
include the type of intervention, target substance and the duration
of the intervention.
Subgroup analysis and investigation of heterogeneity
We will investigate the cause of heterogeneity between studies by
the following subgroup analyses, should sufficient data be avail-
able.
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• Types of psychological or social interventions (e.g.
behavioural, motivational or attachment-based), or both
• Recipients of intervention (individual, couple, family,
mothers, fathers)
• Duration of intervention (short intervention of one session,
medium intervention of up to 6 sessions, extended intervention
of more than 6 sessions)
• Length of follow-up
• Family composition (number of children, parents within
household)
Sensitivity analysis
We will conduct a sensitivity analysis by repeating all previous
analyses with the exclusion of study data that are:
• at high risk of selection bias (random sequence generation
or allocation concealment);
• converted for the purposes of data entry (e.g. where
standard deviations have been estimated from the standard error
of the mean, 95% CIs);
• completer-only rather than intention-to-treat; and
• mean change scores rather than post-intervention scores.
’Summary of findings’ table
We will assess the overall quality of the evidence for the pri-
mary outcome using the GRADE system. TheGrading of Recom-
mendation, Assessment, Development and Evaluation (GRADE)
Working Group developed a system for grading the quality of ev-
idence (Guyatt 2008; Guyatt 2011; Oxman 2004), which takes
into account issues not only related to internal validity but also to
external validity, such as directness of results. We will present the
main findings of the review in a transparent and simple tabular
format in a ’Summary of findings’ table. This will provide key
information concerning the quality of evidence, the magnitude of
effect of the interventions examined and the sum of the available
data for the main outcomes.
The GRADE system assigns four levels of evidence, that should
be interpreted as follows.
• High: we are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: we are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
• Low: our confidence in the effect estimate is limited. The
true effect may be substantially different from the estimate of the
effect.
• Very low: we have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect.
Data from RCTs start at the high level of evidence, and then are
lowered by one or two levels for the following reasons.
• Serious (reduced by one level) or very serious (reduced by
two levels) study limitation for risk of bias.
• Serious (reduced by one level) or very serious (reduced by
two levels) inconsistency between study results.
• Some (reduced by one level) or major (reduced by two
levels) uncertainty about directness (the correspondence between
the population, the intervention, or the outcomes measured in
the studies actually found, and those under consideration in our
review).
• Serious (reduced by one level) or very serious (reduced by
two levels) imprecision of the pooled estimate.
• Strong suspicion of publication bias (reduced by one level).
A C K N OW L E D G E M E N T S
This review protocol has been produced to guide a systematic re-
view funded by theNational Institute of Health Research (NIHR)
personal fellowships awarded to Ruth McGovern (NIHR PDF-
2014-07-045). The views expressed are those of the authors and
not necessarily those of the NHS, the NIHR or the Department
of Health.
We are grateful to Zuzana Mitrova (Managing Editor) and Pro-
fessor Walter Ling (Contact Editor) for the Cochrane Drugs and
Alcohol Group (CDAG) and the CDAG for their helpful com-
ments and suggestions on this protocol.
8Effectiveness of psychosocial interventions for reducing parental substance misuse (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
Additional references
Alcoholics Anonymous 2002
Alcoholics Anonymous. The Big Book 4th Edition.
www.aa.org/pages/en_US/alcoholics-anonymous 2002
(accessed 2nd October 2017).
Anderson 2009
Anderson P, Chisholm D, Fuhr D. Effectiveness and cost-
effectiveness of policies and programmes to reduce the harm
caused by alcohol. Lancet 2009;373(9682):2234–46.
Baker 2014
Baker B, Kerr T, Alfred GT, Fortin M, Nguyen P, Wood
E, et al. High prevalence of exposure to the child welfare
system among street-involved youth in a Canadian setting:
implications for policy and practice. BMC Public Health
2014;197. [DOI: 10.1186/1471-2458-14-197
Baker 2015
Baker R, Orton E, Tata LJ, Kendrick D. Risk factors for
long-bone fractures in children up to 5 years of age: a nested
case-control study. Archives of Disease in Childhood 2015;
100(5):432–7.
Bandura 1969
Bandura A. Principles of Behaviour Modification. New York
(NY): Holt, Rinehart and Winston, 1969.
Barczyk 2013
Barczyk AN, Yuma-Guerrero P, von Sternberg K, Velasquez
MM, Brown J, Maxson T, et al. Risky drinking among
parents of pediatric trauma patients. Journal of Trauma
Acute Care Surgery 2013;75(4):676–81.
Barth 2005
Bartch RP, Landsverk J, Chamberlain P, Reid JB, Rolls
JA, Hurlburt MS, et al. Parent-training programs in
child welfare services: planning for a more evidence-based
approach to serving biological parents. Research on Social
Work Practice 2005;15(5):353–71.
Beck 1993
Beck AT, Wright FD, Newman CF, Liese BS. Cognitive
Therapy of Substance Abuse. New York (NY): Guilford Press,
1993.
Cassidy Giglia 2012
Cassidy TM, Giglia RC. Psychosocial and cultural
interventions for reducing alcohol consumption during
lactation. Cochrane Database of Systematic Reviews 2012,
Issue 3. [DOI: 10.1002/14651858.CD009707
Catalano 1999
Catalano RF, Gainey RR, Fleming CB, Haggerty KP,
Johnson NO. An experimental intervention with families of
substance abusers: one-year follow-up of focus on families
project. Addiction 1999;94(2):241–54.
Daley 1998
Daley M, Argeriou M, McCarty D. Substance abuse
treatment for pregnant women: a window of opportunity?.
Addictive Behaviors 1998;23(2):239–49.
Damashek 2009
Damashek A, Williams NA, Sher K, Peterson L. Relation
of caregiver alcohol use to unintentional childhood injury.
Journal of Pediatric Psychology 2009;34(4):344–53.
Davies 2013
Davies S. Chief Medical Officers Report 2012. Our
children deserve better: prevention pays. www.gov.uk/
government/publications/chief-medical-officers-annual-
report-2012-our-children-deserve-better-prevention-pays
accessed 2nd October 2017.
Dawe 2007
Dawe S, Frye S, Best D, Moss D, Atkinson J, Evans C,
et al. Drug use in the family: impacts and implications
for children. ACT: Australian National Council on Drugs
2007.
De Leon 2000
De Leon, G. The therapeutic community: theory, model and
method. New York: Springer Publishing Company, 2000.
Deeks 2001
Deeks JJ, Altman DG, Bradburn MJ. Statistical methods
for examining heterogeneity and combining results from
several studies in meta-analysis. In: Egger M, Davey Smith
G, Altman DG editor(s). Systematic Reviews in Health Care.
2nd Edition. London: BMJ Books, 2001.
Degenhardt 2012
Degenhardt L, Hall W. Extent of illicit drug use and
dependence, and their contribution to the global burden of
disease. Lancet 2012;9810(379):55–70.
Degenhardt 2013
Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ,
Charlson FJ, Hall WD, et al. Global burden of disease
attributable to illicit drug use and dependence: findings
from the Global Burden of Disease Sttudy 2010. Lancet
2013;382(13):1564–74.
Department for Education 2016
Department for Education. Characteristics of children
in need: 2015-2016. www.gov.uk/government/statistics/
characteristics-of-children-in-need-2015-to-2016 (accessed
2nd October 2017).
Dobkin 2002
Dobkin PL, Civita MD, Paraherakis A, Gill K. The role
of functional social support in treatment retention and
outcomes among outpatient adult substance abusers.
Addiction 2002;97(3):347–56.
Donaldson 2016
Donaldson CD, Handren LM, Crano WD. The enduring
impact of parents’ monitoring, warmth, expectancies, and
alcohol use on their children’s future binge drinking and
arrests: a longitudinal analysis. Prevention Science 2016;17
(5):606–14.
Earnshaw 2013
Earnshaw V, Smith L, Copenhaver M. Drug addiction
stigma in the context of methadone maintenance therapy:
9Effectiveness of psychosocial interventions for reducing parental substance misuse (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
an investigation into understudied sources of stigma.
International Journal of Mental Health and Addiction 2013;
11(1):110–22.
EMCDDA 2010
Children’s voices: experiences and perceptions of
European children on drug and alcohol issues.
www.emcdda.europa.eu/publications/thematic-papers/
childrens-voices_en 2010 (accessed 2nd October 2017).
Forrester 2000
Forrester D. Parental substance misuse and child protection
in a British sample. Child Abuse Review 2000;9(4):235–46.
Forrester 2006
Forrester D, Harwin J. Parental substance misuse and child
care social work: findings from the first stage of a study
of 100 families. Child & Family Social Work 2006;11(4):
325–35.
Gates 2007
Gates LB, Akabas SH. Developing strategies to integrate
peer providers into the staff of mental health agencies.
Administration and Policy in Mental Health and Mental
Health Services Research 2007;34(3):293–306.
Guyatt 2008
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y,
Alonso-Coello P, et al. GRADE: an emerging consensus on
rating quality of evidence and strength of recommendations.
BMJ 2008;336(7560):924–6.
Guyatt 2011
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek
J, et al. GRADE guidelines 1. Introduction-GRADE
evidence profiles and summary of findings tables. Journal of
Clinical Epidemiology 2011;64(4):383–94.
Health and Social Care Information Centre 2013
Lifestyle Statistics, Health and Social Care Information
Centre. Statistics on alcohol: England, 2013. Health
and Social Care Information Centre: www.hscic.gov.uk/
catalogue/PUB10932 2013 (accessed 2nd October 2017).
Higgins 2011
Higgins JP, Green S, editor(s). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 (updated
March 2011). The Cochrane Collaboration, 2011.
Available from handbook.cochrane.org. The Cochrane
Collaboration.
Holland 2014
Holland S, Forrester D, Williams A, Copello A. Parenting
and substance misuse: understanding accounts and realities
in child protection contexts. British Journal of Social Work
2014;44(6):1491–507.
Hughes 2008
Hughes K, Anderson Z, Morleo M, Bellis MA. Alcohol,
nightlife and violence: the relative contributions of drinking
before and during nights out to negative health and criminal
outcomes. Addiction 2008;103(1):60–5.
Jääskeläinen 2016
Jääskeläinen M, Holmila M, Notkola I, Raitasalo K. Mental
disorders and harmful substance use in children of substance
abusing parents: a longitudinal register-based study on
complete birth cohort born in 1991. Drug and Alcohol
Review 2016;35(6):728–40.
Kaminski 2008
Kaminski JW, Valle LA, Filene JH, Boyle CL. A meta-
analytic review of components associated with parent
training program effectiveness. Journal of Abnormal Child
Psychology 2008;36(4):567–9.
Kaner 2016
Kaner E, McGovern R. Who’s minding the children - do
we need to focus on reducing intergenerational risk due to
parents who drink problematically?. Addiction 2016;111
(10):1804–5.
Kelley 2010
Kelley ML, Braitman A, Henson JM, Schroeder V, Ladage
J, Gumienny L. Relationships among depressive mood
symptoms and parent and peer relations in collegiate
children of alcoholics. American Journal of Orthopsychiatry
2010;80(2):2004–12.
Kendler 2013
Kendler KS, Gardner CO, Edwards A, Hickman M,
Heron J, Macleod J, et al. Dimensions of parental alcohol
use/problems and offspring temperament, externalizing
behaviors, and alcohol use/problems. Alcoholism: Clinical
& Experimental Research 2013;37(12):2118–27.
Klostermann 2011
Klostermann K, Chen R, Kelley ML, Schroeder VM,
Braitman AL, Mignone T. Coping behavior and depressive
symptoms in adult children of alcoholics. Substance Use &
Misuse 2011;46(9):1162–8.
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching
for studies. In: Higgins JP, Green S, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration,
2011. Available from handbook.cochrane.org. Cochrane
Collaboration.
Lim 2012
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Memish
ZA, et al. A comparative risk assessment of burden of disease
and injury attributable to 67 risk factors and risk factor
clusters in 21 regions, 1990-2010: a systematic analysis for
the Global Burden of Disease Study 2010. Lancet 2012;380
(9859):2224–60.
Lui 2008
Lui S, Terplan M, Smith EJ. Psychosocial interventions for
women enrolled in alcohol treatment during pregnancy.
Cochrane Database of Systematic Reviews 2008, Issue 3.
[DOI: 10.1002/14651858.CD006753.pub2
Lundahl 2013
Lundahl B, Moleni T, Burke BL, Butters R, Tollefson
D, Butler C, et al. Motivational interviewing in medical
care settings: a systematic review and meta-analysis of
randomized controlled trials. Patient Education and
Counselling 2013;93(2):157–68.
10Effectiveness of psychosocial interventions for reducing parental substance misuse (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Malone 2002
Malone SM, Lacono WG, McGue M. Drinks of the father:
father’s maximum number of drinks consumed predicts
externalizing disorders, substance use, and substance
use disorders in preadolescent and adolescent offspring.
Alcoholism: Clinical & Experimental Research 2002;26(12):
1823–32.
Malone 2010
Malone SM, McGue M, Lacono W. Mothers’ maximum
drinks ever consumed in 24 hours predicts mental health
problems in adolescent offspring. Journal of Child Psychology
& Psychiatry 2010;51(9):1067–75.
Manning 2009
Manning V, Best D, Faulker N, Titherington E. New
estimates of the number of children living with substance
misusing parents: results from UK national household
surveys. BMC Public Health 2009;9(377). [DOI: 10.1186/
1471-2458-9-377
Manning 2011
Manning V. Estimates of the number of infants (under the
age of one year) living with substance misusing parents.
www.nspcc.org.uk/globalassets/documents/research-
reports/estimates-number-infants-living-with-substance-
misusing-parents-report.pdf 2011 (accessed 2nd October
2017).
Marlatt 1985
Marlatt GA. Cognitive factors in the relapse process. In:
Marlatt GA, Gordon JR editor(s). Relpase Prevention. New
York (NY): Guilford Press, 1985:128–200.
McBride 2003
McBride CM, Emmons KM, Lipkus IM. Understanding
the potential of teachable moments: the case of smoking
cessation. Health Education Research 2003;18(2):156–70.
McLaughlin 2014
McLaughlin AE, Macdonald G, Livingstone N, McCann
M. Interventions to build resilience in children of problem
drinkers. Cochrane Database of Systematic Reviews 2014,
Issue 8. [DOI: 10.1002/14651858.CD011237
McLellan 1999
McLellan AT, Hagan TA, Levine M, Meyers K, Gould
F, Bencivengo M, et al. Does clinical case management
improve outpatient addition treatment. Drug and Alcohol
Dependence 1999;55:91–103.
Meichenbaum 1977
Meichenbaum D. Cognitive behaviour modification.
Scandinavian Journal of Behaviour Therapy 1977;6(4):
185–92.
Miller 1983
Miller WR. Motivational interviewing with problem
drinkers. Behavioural Psychotherapy 1983;11:147–72.
Miller 1991
Miller WR, Rollnick S.Motivational Interviewing: Preparing
People to Dhange Addictive Behaviour. New York (NY):
Guildford Press, 1991.
Miller 2003
Miller WR, Yahne CE, Tonigan JS. Motivational
interviewing in drug abuse services: a randomized trial.
Journal of Consulting Clinical Psychology 2003;71(4):
754–63.
Miller 2013
Miller WR, Rollnick S. Motivational Interviewing: Helping
People to Change. 3rd Edition. New York (NY): Guilford
Press, 2013.
Monti 1989
Monti PM, Abrams DB, Kadden RM, Cooney NL. Treating
Alcohol Dependence: a Coping Skills Training Guide in the
Treatment of Alcoholism. New York (NY): Guilford Press,
1989.
NICE 2016
National Institute for Health and Care Excellence. Drug
misuse prevention. NICE Guidance 2016.
Nutt 2010
Nutt D, King L, Phillips L. Drug harms in the UK: a
multicriteria decision analysis. Lancet 2010;376(9752):
1558–65.
O’Farrell 1993
O’Farrell TJ. Couples relapse prevention sessions after a
behavioural marital therapy couples group program. In:
O’Farrell TJ editor(s). Treating Alcohol Problems: Marital
and family interventions. New York (NY): Guilford Press,
1993:305–26.
Ohannessian 2012
Ohannessian CM. Parental problem drinking and
adolescent psychosocial adjustment: the mediating role of
adolescent-parent communication. Journal of Research on
Adolescence 2012;22(3):498–511.
Oxman 2004
Oxman AD, GRADE Working Group. Grading quality of
evidence and strength of recommendations. BMJ 2004;328
(19):1490–4.
Pallaveshi 2014
Pallaveshi L, Balachandra K, Subramanian P, Rudnick A.
Peer-led and professional-led group interventions for people
with co-occurring disorders: a qualitative study. Community
Mental Health Journal 2014;50(4):388–94.
Raistrick 2006
Raistrick D, Health N, Godfrey C. Review of the
effectiveness of treatment for alcohol problems. National
Treatment Agency 2006.
Raitasalo 2015
Raitasao K, Holmila M, Autti-Rämö I, Notkola I,
Tapanainen H. Hospitalisations and out-of-home
placements of children of substance-abusing mothers: a
register-based cohort study. Drug and Alcohol Review 2015;
34(1):38–45.
Review Manager 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
11Effectiveness of psychosocial interventions for reducing parental substance misuse (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Ryan 2014
Ryan R, Cochrane Consumers and Communication Review
Group. Heterogeneity and subgroup analyses in Cochrane
Consumers and Communication Review Group reviews:
planning the analysis at protocol stage. cccrg.cochrane.org
(accessed 11 November 2016).
Rëhm 2009
Rëhm J, Mathers C, Popova S, Thavorncharoensap M,
Teerawattananon Y, Patra J. Global burden of disease and
injury and economic cost attributable to alcohol use and
alcohol use disorders. Lancet 2009;373:2223–33.
SAMHSA 2009
Substance Abuse and Mental Health Services Admin-
istration. The NSDUH report: Children living with
substance-dependent or substance-abusing parents:
2002 to 2007. www.ok.gov/odmhsas/documents/Chil-
dren%20Living%20with%20Substance%20Dependent%20or%20Abusing%20Parents%202002-
2007.pdf 2009 (accessed 2nd October 2017).
Shedler 2010
Shedler J. The efficacy of psychodynamic psychotherapy.
American Psychologist 2010;63(2):98–109.
Simpson 2008
Simpson DD, Flynn PM. Drug Abuse Treatment Outcome
Studies (DATOS): a national evaluation of treatment
effectiveness. In: Fisher G, Roget N editor(s). Encyclopedia
of Substance Abuse Prevention, Treatment, and Recovery.
Thousand Oaks (CA): Sage Publishing, 2008:303–7.
Slesnick 2013
Slesnick N, Erdem E. Efficacy of ecologically-based
treatment with substance-abusing homeless mothers:
substance use and housing outcomes. Journal of Substance
Abuse Treatment 2013;45(5):416–25.
Stratton 2011
Stratton P. The evidence base of systemic family and couples
therapies. The Asscoiation for Family Therapy & Systemic
Practice, available from www.aft.org.uk 2011 (accessed 2nd
October 2017).
Taplin 2015
Taplin S, Mattrick RP. The nature and extent of child
protection involvement among heroin-using mothers in
treatment: high rates of reports, removals at birth and
children in care. Drug and Alcohol Review 2015;34(1):31–7.
Terplan 2015
Terplan M, Ramanadhan S, Locke A, Longinaker N, Lui
S. Psychosocial interventions for pregnant women in
outpatient illicit drug treatment programs compared to
other interventions. Cochrane Database of Systematic Reviews
2015, Issue 4. [DOI: 10.1002/14651858.CD006037.pub3
Tiffany 1990
Tiffany ST. A cognitive model of drug urges and drug-use
behavior: role of automatic and nonautomatic processes.
Psychological Review 1990;97(2):147–68.
Torvik 2011
Torvik FA, Rognmo K, Ask H, Røysamb E, Tambs K.
Parental alcohol use and adolescent school adjustment in
the general population: results from the HUNT study.
BMC Public Health 2011;11(706). [DOI: 10.1186/
1471-2458-11-706
Traube 2012
Traube D. The missing link to child safety, permanency, and
well-being: addressing substance misuse in child welfare.
Social Work Research 2012;36(2):83–7.
Tyrrell 2012
Tyrrell EG, Orton E, Tata LJ, Kendrick E. Children at risk
of medicinal and non-medicinal poisoning: a population-
based case-control study in general practice. British Journal
of General Practice 2012;62(605):e827–33.
World Health Organization 2009
World Health Organisation. Global health risks: mortality
and burden of disease attributed to selected major
risks. www.who.int/healthinfo/global_burden_disease/
GlobalHealthRisks_report_full.pdf 2009 (accessed 2nd
October 2017).
World Health Organization 2011
World Health Organization. Global Status report on
alcohol and health. www.who.int/substance_abuse/
publications/global_alcohol_report/msbgsruprofiles.pdf
2011 (accessed 2nd October 2017).
Yoon 2013
Yoon G, Westermeyer J, Kuskowski MA, Nesheim L.
Impact of the number of parents with alcohol use disorder
on alcohol use disorder in offspring: a population-based
study. Journal of Clinical Psychiatry 2013;74(8):676–81.
∗ Indicates the major publication for the study
12Effectiveness of psychosocial interventions for reducing parental substance misuse (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. substance-related disorders/ or alcohol-related disorders/ or amphetamine-related disorders/ or cocaine-related disorders/ or drug
overdose/ or inhalant abuse/ or marijuana abuse/ or opioid-related disorders/ or phencyclidine abuse/ or psychoses, substance-induced/
or substance abuse, intravenous/ or substance withdrawal syndrome/ or alcohol withdrawal delirium/ or alcohol withdrawal seizures/
2. ((stimulant* or polydrug* or drug* or substance) adj6 (abus* or dependen* or addict* or disorder* or intoxicat* or misuse*)).ab,ti.
3. exp alcohol drinking/
4. (alcohol adj3 (dependen* or drink* or intoxicat* or abus* or misus* or risk* or consum* or excess* or reduc* or
intervention*)).ab,ti.
5. (drink* adj3 (excess or heavy or heavily or harm or harmful or hazard* or risky or binge or harmful or problem*)).ab,ti..
6. (addict* or abstain* or abstinen*).ab,ti.
7. (heroin or methadone or temegesic or subutex or opiate* or crack cocaine or cocaine or ecstasy or methamphetamine* or crystal
meth or amphetamine* or cannabis or marijuana or marihuana or lsd or magic mushrooms or mephedrone or khat or cathinone or
ketamine or steroid* or performance enhancing drug* or gammahydroxybutrate or ghb or amyl nitrate).ab,ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. maternal deprivation/ or parent-child relations/ or father-child relations/ or mother-child relations/ or parenting/ or paternal
behavior/ or paternal deprivation/ or nuclear family/ or exp parents/ or single-parent family/
10. (parent or parents or parental or guardian* or mother or maternal or father or paternal or mum or dad).ab,ti.
11. 9 or 10
12. psychotherapy/ or exp behavior therapy/ or exp cognitive therapy/ or exp relaxation therapy/ or gestalt therapy/ or narrative
therapy/ or nondirective therapy/
13. play therapy/ or exp psychoanalytic therapy/ or exp psychotherapeutic processes/ or psychotherapy, brief/ or psychotherapy,
multiple/ or psychotherapy, psychodynamic/
14. psychotherapy, rational-emotive/ or reality therapy/
15. socioenvironmental therapy/
16. counseling/ or exp directive counseling/
17. (motivat* adj5 (interview* or therap* or consult* or intervention* or enhance*)).ab,ti.
18. (brief adj3 intervention* ).ab,ti.
19. (cognit* adj2 (train* or behavior* or therap* or technique* or skill*)).ab,ti.
20. ((psychodynamic or psychosocial) adj2 (therap$ or treatment$ or intervention$ or program$)).ab,ti.
21. (psychotherap* or counsel* or residential rehabilitation).ab,ti.
22. ((relaxation or imagery) adj2 (therap$ or technique$)).ab,ti.
23. (family adj2 therap*).ab,ti.
24. (case adj2 management).ab,ti.
25. ((coping skill* or cbst or self control or assertive*) adj2 (training or therap*)).ab,ti.
26. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
27. (randomized controlled trial or controlled clinical trial).pt.
28. (randomized or placebo).ab.
29. clinical trials as topic.sh.
30. randomly.ab.
31. trial.ti.
32. 27 or 28 or 29 or 30 or 31
33. exp animals/ not humans.sh.
34. 32 not 33
35. 8 and 11 and 34
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Appendix 2. Criteria for ’risk of bias’ assessment adapted to the addiction field
Item Judgment Description
1. Random sequence generation (selection
bias)
Low risk The investigators describe a random component in the sequence gener-
ation process such as: random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing dice;
drawing of lots; minimiSation
High risk The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgement of
the clinician; results of a laboratory test or a series of tests; availability of
the intervention
Unclear risk Insufficient information about the sequence generation process available
to permit a judgement of low or high risk
2. Allocation concealment (selection bias) Low risk Investigators enrolling participants could not foresee assignment because
one of the following, or an equivalent method, was used to conceal alloca-
tion: central allocation (including telephone, web-based, and pharmacy-
controlled, randomisation); sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed envelopes
High risk Investigators enrolling participants could possibly foresee assignments
because one of the following methods was used: open random allocation
schedule (e.g. a list of random numbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or
not sequentially numbered); alternation or rotation; date of birth; case
record number; or any other explicitly unconcealed procedure
Unclear risk Insufficient information available to permit a judgement of low or high
risk This is usually the case if themethod of concealment is not described,
or not described in sufficient detail to allow a definite judgement
3. Blinding of participants and providers
(performance bias)
Objective outcomes
Low risk No blinding, or incomplete blinding, but the review authors judge that
the outcome is not likely to be influenced by lack of blinding
Blinding of participants and key study personnel ensured, and unlikely
that the blinding could have been broken
High risk No blinding, or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
Unclear risk Insufficient information available to permit a judgement of low or high
risk
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(Continued)
4. Blinding of participants and providers
(performance bias)
Subjective outcomes
Low risk Blinding of participants and providers ensured and unlikely that the
blinding could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
Unclear risk Insufficient information available to permit a judgement of low or high
risk
5. Blinding of outcome assessor (detection
bias)
Objective outcomes
Low risk No blinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
Unclear risk Insufficient information available to permit a judgement of low or high
risk
6.Blinding of outcome assessor (detection
bias)
Subjective outcomes
Low risk Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
7. Incomplete outcome data (attrition bias)
For all outcomes except retention in treat-
ment or dropout
Low risk Any one of the following:
• no missing outcome data;
• reasons for missing outcome data unlikely to be related to true
outcome (for survival data, censoring unlikely to be introducing bias);
• missing outcome data balanced in numbers across intervention
groups, with similar reasons for missing data across groups;
• for dichotomous outcome data, the proportion of missing
outcomes compared with observed event risk is not enough to have a
clinically relevant impact on the intervention effect estimate;
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• for continuous outcome data, plausible effect size (difference in
means or standardized difference in means) among missing outcomes is
not enough to have a clinically relevant impact on observed effect size;
• missing data have been imputed using appropriate methods
• all randomized patients are reported/analyzed in the group they
were allocated to by randomisation irrespective of non-compliance and
co-interventions (intention-to-treat).
High risk Any one of the following:
• reason for missing outcome data likely to be related to true
outcome, with either imbalance in numbers or reasons for missing data
across intervention groups;
• for dichotomous outcome data, the proportion of missing
outcomes compared with observed event risk is enough to induce
clinically relevant bias in the intervention effect estimate;
• for continuous outcome data, plausible effect size (difference in
means or standardized difference in means) among missing outcomes is
enough to induce clinically relevant bias in observed effect size;
• ‘as-treated’ analysis done with substantial departure of the
intervention received from that assigned at randomisation.
Unclear risk Insufficient information available to permit a judgement of low or high
risk (e.g. number randomized not stated, no reasons for missing data
provided; number of drop out not reported for each group)
8. Selective reporting (reporting bias) Low risk Either of the following:
• the study protocol is available and all of the study’s prespecified
(primary and secondary) outcomes that are of interest in the review
have been reported in the prespecified way;
• the study protocol is not available, but it is clear that the published
reports include all expected outcomes, including those that were
prespecified (convincing text of this nature may be uncommon).
High risk Any one of the following:
• not all of the study’s prespecified primary outcomes have been
reported;
• one or more primary outcomes is reported using measurements,
analysis methods or subsets of the data (e.g. subscales) that were not
prespecified;
• one or more reported primary outcomes were not prespecified
(unless clear justification for their reporting is provided, such as an
unexpected adverse effect);
• one or more outcomes of interest in the review are reported
incompletely so that they cannot be entered in a meta-analysis;
• the study report fails to include results for a key outcome that
would be expected to have been reported for such a study.
Unclear risk Insufficient information available to permit a judgement of low or high
risk
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9. Other bias Low risk No difference in the importance covariates (e.g. gender or type of sub-
stance misused) between study groups at baseline
No risk of contamination of intervention effects (e.g. practitioner is not
delivering more than one study intervention)
High risk Any one of the following:
• Baseline between study group imbalance on important covariates
(e.g. gender or type of substance misused)
• Contamination of intervention effects (e.g. practitioner delivers
more than one study intervention to different participants)
Unclear risk Insufficient information to form judgement of low or high risk for con-
founding or contamination
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